By Timothy S. Donahue
Top Takeaways:
- Comment window: FDA opens public comment period on draft flavored e-cigarette PMTA guidance.
- Evidence bar: Agency indicates a greater burden to prove that adult benefits outweigh youth risks.
- Regulatory signal: The framework reinforces a youth-first standard that shapes future authorizations.
The FDA is seeking feedback, but the overall direction is already established. The U.S. Food and Drug Administration has opened a public comment period on its draft guidance outlining how it will evaluate premarket applications for flavored e-cigarettes, sharpening its focus on youth risk and the level of adult benefit required for authorization.
The document, titled “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk,” explains the agency’s current stance on how flavored products must show they are suitable for protecting public health (APPH).
At the core is a well-known—but now clearer—standard. Applicants must demonstrate that flavored products offer a tangible benefit to adult smokers compared to tobacco-flavored options, and that this benefit outweighs the risk of youth initiation and use.
The guidance reinforces a risk-balancing framework that has influenced FDA decision-making in recent years, while providing more structure on how that balance is assessed.
Among the key areas outlined:
- The role of flavored products in youth uptake and initiation
- A “graduated, risk-proportionate” evaluation of products
- Evidence requirements demonstrating switching or significant cigarette reduction among adults
- Study approaches to assess youth risk
- The potential use of access-restriction technologies on devices
The focus on comparative benefit—especially compared to tobacco-flavored products—indicates a higher standard of evidence for flavored applications, which have historically received more scrutiny from the agency.
The guidance does not create new laws but offers insight into how the FDA plans to interpret existing statutory standards under the Family Smoking Prevention and Tobacco Control Act.
If finalized, it will act as a crucial reference for companies preparing or defending premarket tobacco product applications (PMTAs), especially as the agency works through a backlog of submissions.
The public comment period runs through May 11, 2026, with submissions accepted via Regulations.gov under docket FDA-2026-D-1817.
